Related Experiment Videos
Five-year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatin-based
M S Piver1, J Malfetano, T R Baker
1Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York 14263.
Gynecologic Oncology
|September 1, 1992
Abstract:
Thirty-two stage IC or stage I grade 3 patients with invasive ovarian adenocarcinoma were treated with 6 months of adjuvant cisplatin-based chemotherapy. With a median follow-up of 60.5 months, there have been three (9%) recurrences. The 5-year progression-free survival was 90.5% and the 5-year survival was 93.3%.